{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:45:22Z","timestamp":1792079122997,"version":"4.4.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n \n \u03b1\n 1<\/jats:sub>\n -Antitrypsin deficiency (AATD) is underdiagnosed despite guidelines for broad testing, and the factors associated with low testing and treatment are not well known.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify factors associated with low AATD testing and augmentation therapy in individuals with chronic obstructive pulmonary disease (COPD) and asthma.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This is a retrospective, multicenter cohort study using national electronic health record data from the Veterans Health Administration from January 1, 2020, to December 31, 2024. Data analysis was conducted from July to October 2025. Participants were individuals with a diagnosis of COPD and\/or asthma (\u22652\n International Classification of Diseases, Ninth Revision,<\/jats:italic>\n or\n International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n codes).\n <\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Individual demographics, comorbidities, tobacco use, rural-urban residence, Social Vulnerability Index (SVI), and drive time to the specialty care facility.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were prevalence of and factors associated with AATD testing and augmentation therapy prescription. Multivariable regression models were used, adjusting sequentially for demographics, comorbidities, tobacco use, rural-urban residence, SVI, and drive time to the specialty care facility.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 2\u202f384\u202f913 individuals with COPD and\/or asthma (mean [SD] age, 64.2 [14.3] years; 178\u202f898 female [7.5%]; 16\u202f778 [0.7%] American Indian or Alaska Native; 14\u202f996 [0.7%] Asian; 331\u202f202 Black or African American [15.3%]; 19\u202f029 [0.9%] Native Hawaiian or Pacific Islander; 1\u202f787\u202f951 White [82.4%]), 138\u202f278 (5.8%) underwent testing. In fully adjusted models, cirrhosis (adjusted odds ratio [aOR], 6.40; 95% CI, 6.29-6.51) and bronchiectasis (aOR, 3.73; 95% CI, 3.59-3.87) were associated with higher odds of testing. Older ages and active tobacco use were associated with lower odds of testing. Rural-urban residence and SVI had similar odds across categories. Longer drive times were associated with progressively lower odds of testing (&amp;gt;90 vs \u226430 minutes; aOR, 0.63; 95% CI, 0.62-0.65). Of 8564 with AATD diagnosis, 320 (3.7%) were prescribed augmentation therapy and showed a similar pattern as testing, occurring less often among patients from minoritized racial and ethnic groups, those actively using tobacco, and those with longer drive times to specialty care, and more often among those with cirrhosis and bronchiectasis.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of individuals with COPD and\/or asthma, AATD testing and augmentation therapy were profoundly low. System-level reform is needed to bridge gaps across age, comorbidities, tobacco use, and health care access.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.39328","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:38Z","timestamp":1792076438000},"page":"e2639328","source":"Crossref","is-referenced-by-count":0,"title":["Disparities in \u03b1\n 1<\/sub>\n -Antitrypsin Deficiency Testing and Treatment in US Adults"],"prefix":"10.1001","volume":"9","author":[{"given":"Arianne K.","family":"Baldomero","sequence":"first","affiliation":[{"name":"Pulmonary, Allergy, Critical Care, and Sleep Medicine, Minneapolis VA Health Care System, Minneapolis, Minnesota"},{"name":"Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis"},{"name":"Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Smith","sequence":"additional","affiliation":[{"name":"Research Department, Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Gravely","sequence":"additional","affiliation":[{"name":"Research Department, Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickram","family":"Tejwani","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Genomic Sciences and Systems Biology, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris H.","family":"Wendt","sequence":"additional","affiliation":[{"name":"Pulmonary, Allergy, Critical Care, and Sleep Medicine, Minneapolis VA Health Care System, Minneapolis, Minnesota"},{"name":"Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"15","key":"zoi261063r1","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJMra1910234","article-title":"Alpha1-antitrypsin deficiency.","volume":"382","author":"Strnad","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi261063r2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1164\/ajrccm\/140.4.961","article-title":"Alpha-1-antitrypsin deficiency: high prevalence in the St. Louis area determined by direct population screening.","volume":"140","author":"Silverman","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"zoi261063r3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3109\/15412555.2012.669433","article-title":"The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction.","volume":"9","author":"Rahaghi","year":"2012","journal-title":"COPD"},{"issue":"3","key":"zoi261063r4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.15326\/jcopdf.3.3.2015.0182","article-title":"The diagnosis and management of alpha-1 antitrypsin deficiency in the adult.","volume":"3","author":"Sandhaus","year":"2016","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"3","key":"zoi261063r5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1164\/rccm.201108-1428CI","article-title":"A review of a1-antitrypsin deficiency.","volume":"185","author":"Stoller","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"zoi261063r6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1513\/AnnalsATS.202406-600FR","article-title":"Detecting alpha-1 antitrypsin deficiency: current state, impediments, opportunities, and future directions.","volume":"22","author":"Stoller","year":"2025","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"zoi261063r7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1164\/rccm.168.7.818","article-title":"American Thoracic Society\/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.","volume":"168","author":"American Thoracic Society","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"zoi261063r8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.7205\/MILMED-D-10-00377","article-title":"High prevalence of chronic obstructive pulmonary disease among veterans in the urban Midwest.","volume":"176","author":"Murphy","year":"2011","journal-title":"Mil Med"},{"issue":"4","key":"zoi261063r9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0749-3797(18)30453-7","article-title":"The association between veteran status and cigarette-smoking behaviors.","volume":"11","author":"Klevens","year":"1995","journal-title":"Am J Prev Med"},{"issue":"2","key":"zoi261063r10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1513\/AnnalsATS.202503-325OC","article-title":"Epidemiology of alpha-1 antitrypsin deficiency in the Veterans Health Administration.","volume":"23","author":"Riley","year":"2026","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"zoi261063r14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12913-019-4574-3","article-title":"Algorithms to identify COPD in health systems with and without access to ICD coding: a systematic review.","volume":"19","author":"Gothe","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"zoi261063r15","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.chest.2024.08.037","article-title":"Alpha-1-antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society meta-analysis and clinical practice guideline.","volume":"167","author":"Hernandez","year":"2025","journal-title":"Chest"},{"issue":"5","key":"zoi261063r16","first-page":"397","article-title":"Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting.","volume":"75","year":"1997","journal-title":"Bull World Health Organ"},{"issue":"5","key":"zoi261063r17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1089\/respcare.12524","article-title":"Alpha-1 antitrypsin deficiency screening using serum protein electrophoresis.","volume":"70","author":"Perales-Af\u00e1n","year":"2025","journal-title":"Respir Care"},{"issue":"1","key":"zoi261063r18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-024-03069-1","article-title":"Rare variants in alpha 1 antitrypsin deficiency: a systematic literature review.","volume":"19","author":"Ferrarotti","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"zoi261063r19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1165\/rcmb.2022-0470OC","article-title":"Comprehensive clinical diagnostic pipelines reveal new variants in alpha-1 antitrypsin deficiency.","volume":"69","author":"Ottaviani","year":"2023","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11","key":"zoi261063r20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"6","key":"zoi261063r21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"zoi261063r22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-018-0501-2","article-title":"Validating the use of veterans affairs tobacco health factors for assessing change in smoking status: accuracy, availability, and approach.","volume":"18","author":"Melzer","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"zoi261063r26","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.70182","article-title":"Defining veteran rurality: an analysis of the U.S. Veterans Health Administration rural\u2013urban taxonomy.","volume":"42","author":"Govier","year":"2026","journal-title":"J Rural Health"},{"issue":"6","key":"zoi261063r28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01441-2020","article-title":"The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes.","volume":"56","author":"Nakanishi","year":"2020","journal-title":"Eur Respir J"},{"issue":"9478","key":"zoi261063r29","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/S0140-6736(05)66781-5","article-title":"Alpha1-antitrypsin deficiency.","volume":"365","author":"Stoller","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"zoi261063r30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00360-2018","article-title":"Trends of testing for and diagnosis of a1-antitrypsin deficiency in the UK: more testing is needed.","volume":"52","author":"Soriano","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"zoi261063r31","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/jcm13040955","article-title":"Detection of alpha-1 antitrypsin levels in chronic obstructive pulmonary disease in respiratory clinics in Spain: results of the EPOCONSUL 2021 Audit.","volume":"13","author":"Calle Rubio","year":"2024","journal-title":"J Clin Med"},{"key":"zoi261063r32","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2147\/COPD.S195847","article-title":"Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency.","volume":"14","author":"Hiller","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"9","key":"zoi261063r33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/thx.2006.075846","article-title":"Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.","volume":"62","author":"Demeo","year":"2007","journal-title":"Thorax"},{"key":"zoi261063r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104262","article-title":"Unique and shared systemic biomarkers for emphysema in alpha-1 antitrypsin deficiency and chronic obstructive pulmonary disease.","volume":"84","author":"Serban","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"zoi261063r35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2025-003585","article-title":"Matrix metalloproteinases and disease severity among PI*MZ and PI*ZZ individuals in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) cohort.","volume":"12","author":"Tejwani","year":"2025","journal-title":"BMJ Open Respir Res"},{"key":"zoi261063r36","doi-asserted-by":"publisher","first-page":"A6145","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A6145","article-title":"Initial characterization of the alpha-1 biomarker consortium.","volume":"211","author":"Goldklang","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"zoi261063r37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.amjmed.2023.06.020","article-title":"Testing patterns and disparities for alpha-1 antitrypsin deficiency.","volume":"136","author":"Riley","year":"2023","journal-title":"Am J Med"},{"issue":"11","key":"zoi261063r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.40290","article-title":"Drive time and receipt of guideline-recommended screening, diagnosis, and treatment.","volume":"5","author":"Baldomero","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi261063r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.28898","article-title":"Geographic disparities by rural-urban status and drive time to care in tobacco treatment for COPD.","volume":"8","author":"Baldomero","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi261063r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100597","article-title":"Guideline-discordant inhaler regimens after COPD hospitalization: associations with rurality, drive time to care, and fragmented care\u2014a United States cohort study.","volume":"26","author":"Baldomero","year":"2023","journal-title":"Lancet Reg Health Am"},{"issue":"9","key":"zoi261063r41","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/ajrccm\/aamag159","article-title":"Geographic disparities in chronic obstructive pulmonary disease inhalers by rurality, drive time, and neighborhood disadvantage.","volume":"212","author":"Baldomero","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"zoi261063r42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1164\/ajrccm.158.1.9712017","article-title":"Survival and FEV1 decline in individuals with severe deficiency of a1-antitrypsin.","volume":"158","author":"Vreim","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"zoi261063r43","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12931-022-02275-4","article-title":"Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry.","volume":"23","author":"Miravitlles","year":"2022","journal-title":"Respir Res"},{"issue":"2","key":"zoi261063r44","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1378\/chest.111.2.394","article-title":"Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of a1-antitrypsin deficiency.","volume":"111","author":"McElvaney","year":"1997","journal-title":"Chest"},{"issue":"4","key":"zoi261063r45","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1378\/chest.128.4.1989","article-title":"Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem.","volume":"128","author":"Stoller","year":"2005","journal-title":"Chest"},{"key":"zoi261063r46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/COPD.S346051","article-title":"Opinions and attitudes of pulmonologists about augmentation therapy in patients with alpha-1 antitrypsin deficiency: a survey of the EARCO Group.","volume":"17","author":"Greulich","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"zoi261063r47","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211014025","article-title":"Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what\u2019s down the road?","author":"Rahaghi","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"issue":"8","key":"zoi261063r48","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1513\/AnnalsATS.202211-954OC","article-title":"Impact of a computerized clinical decision support system to improve chronic obstructive pulmonary disease diagnosis and testing for alpha-1 antitrypsin deficiency.","volume":"20","author":"Campos","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"zoi261063r49","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.12200","article-title":"An electronic health record-based strategy to enhance detection of alpha-1 antitrypsin deficiency.","author":"Nathani","year":"2024","journal-title":"Respir Care"},{"key":"zoi261063r23","volume-title":"VIReC Research User Guide: PSSG Geocoded Enrollee Files, 2015 Edition","author":"US Department of Veterans Affairs Information Resource Center","year":"2016"},{"key":"zoi261063r11","unstructured":"Agency for Healthcare Research and Quality. Overview of VHA patient, veteran, and non-veteran populations and characteristics: National Healthcare Quality and Disparities Report. November 2020. Accessed May 25, 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK578553\/"},{"key":"zoi261063r12","unstructured":"STROBE: strengthening the reporting of observational studies in epidemiology. Accessed May 25, 2026. https:\/\/www.strobe-statement.org\/"},{"key":"zoi261063r13","unstructured":"VA Health Systems Research. Corporate Data Warehouse (CDW). Accessed May 25, 2026. https:\/\/www.hsrd.research.va.gov\/for_researchers"},{"key":"zoi261063r24","unstructured":"Agency for Toxic Substances and Disease Registry. Place and health: geospatial research, analysis, and services program (GRASP)\u2014Social Vulnerability Index. July 22, 2024. Accessed September 11, 2026. https:\/\/www.atsdr.cdc.gov\/place-health\/php\/svi\/index.html"},{"key":"zoi261063r25","unstructured":"US Department of Agriculture, Economic Research Service. Rural-Urban Community Area Codes, version 2010. November 16, 2021. Accessed September 11, 2026. https:\/\/www.ers.usda.gov\/data-products\/rural-urban-commuting-area-codes\/"},{"key":"zoi261063r27","unstructured":"US Department of Veterans Affairs. Health economics resource center: estimating travel costs. Accessed September 11, 2026. https:\/\/www.herc.research.va.gov\/include\/page.asp?id=travel-costs"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855349\/baldomero_2026_oi_261063_1791405255.28629.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:40Z","timestamp":1792076440000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.39328","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}